A 2020 survey of 500 parents and children in the U.S. conducted by the Center for Information and Study on Clinical Research Participation and commissioned by Parexel has yielded insights into why families choose to participate in clinical research and how to design clinical trials to better fit their needs, according to the survey report.
While survey respondents expressed largely positive views of pediatric clinical research, actual participation in pediatric research remains low. Only 16.7% of clinical trials registered on the World Health Organization’s portal involve pediatric patients, and only 12% of trials registered on clinicaltrials.gov are pediatric trials, even though children contributed to almost 60% of the total disease burden of the conditions being studied. As a result of low pediatric participation, the majority of drugs prescribed to children are only evaluated in adults.
“Understanding patient health journeys and study volunteer experiences is critical to designing more patient-friendly trials that ultimately enhance pediatric patient participation, so that we can continue to develop newer, safer and more effective drugs for children,” said Ken Getz, Founder and Chairman at CISCRP.
The Pediatric Perceptions & Insights Study was created, in part, as an outgrowth of questions included in the baseline CISCRP Perceptions & Insights Study that is conducted biennially in adult populations, which gauges public and patient perceptions, motivations, and experiences regarding clinical research participation. Its goal is to monitor trends and identify opportunities to better inform and engage the public and patients as stakeholders and partners in contributing to the clinical research enterprise.
For more of the survey’s findings, click here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.